Member Info for Moneymunch

There's no doubt that the ex CEO's vested share options have been accelerated long before their expiry date, and maybe this is because some sort of T/O, Merger or Strategic Investment is in the pipeline, whereby existing share options in place could be restructured to accomodate the new controlling entity which could be detrimental to existing options held, especially those of ex-employees, and maybe the acceleration of EVG's ex CEO share options were approved by the BoD etc as part of his severance package, as he makes way for the new incoming CEO....Gla ;-)

.........................

My Company Is Being Acquired: What Happens To My Stock Options? (Part 1)

Key Points

Your company cannot terminate vested options, unless the plan allows it to cancel all outstanding options (both unvested and vested) upon a change in control.

In this situation, your company may repurchase the vested options.

The focus of concern is on what happens to your unvested options.

Some plans provide latitude to your company's board of directors (or its designated committee) to determine the specifics of any acceleration of unvested options.

The agreements may provide the board with absolute discretion as to whether to accelerate the vesting at all. Alternatively, the stock plan documents may require acceleration.

Timing Of Acceleration

Acceleration most commonly occurs at the moment just prior to the merger or "qualifying event."

The actual date of acceleration is generally the effective date of the merger or "qualifying event," which likely requires shareholder approval. Acceleration most commonly occurs at the moment just prior to the merger or "qualifying event."

The unvested options usually are not accelerated earlier than the date of closing in case the deal does not go through. Should the deal not close, your options will not be accelerated. Check your plan documents for guidance on the timing. When not specified, the timing of acceleration is at the board’s discretion.

hTtps://www.mystockoptions.com/articles/my-company-is-being-acquired-what-happens-to-my-stock-options-part-1

We've had news along the way radar, you were the numptie who said the speculaion that SFX-01 would be considered for Covid-19 patient trials was rubbish....remember???.....Gla Holders.....potential transformational news stacking UP on several fronts... ;-)

16/6/20

"with patients offered the chance to participate immediately after their diagnosis"

Researchers secured funding from LifeArc to conduct an investigator led, prospective, randomised, double-blind placebo-controlled trial, conducted in the UK, of patients hospitalised with COVID-19.

Investigating a sample size of 300 subjects, the study will compare outcomes for 300mg SFX-01 taken orally, once daily, plus best standard of care (BSC) versus placebo taken orally, once daily plus BSC. The primary outcome of the trial is the clinical status of patients on day 15 based on a seven point scale, recommended by the World Health Organisation as the optimal clinical trial endpoint for COVID-19 studies.

The trial will be conducted in up to six sites across Scotland and the north of England with first patient visit anticipated to happen in July.

https://www.lifearc.org/funding/covid-19-funding/sfx-01/

and no doubt a coincidence but still no Covid-19 deaths reported in Scotland since 12th July......the SFX-01 effect??? Gla ;-)

Scottish numbers: 24 July 2020

20 new confirmed cases of COVID-19; this is 0.4% of newly tested individuals (note that there were actually 22 new cases, although two previous positive cases have been de-notified and are now classified as negative; as such there is a net increase of 20 positive cases)
0 new reported death(s) of people who have tested positive
2 people were in intensive care last night with confirmed COVID-19
278 people were in hospital with confirmed COVID-19
16,338 new tests for COVID-19 that reported results
10 new suspected COVID-19 cases in adult care homes on 23 July

It would appear that the ex CEO is exercising all his share options, many of which had several years before expiry, which suggests that he's not taking any chances of loosing them null and void, which would normally happen on any restructuring of share options following a T/O or Strategic Partnership Investment etc....and perhaps reason why we're still awaiting news on the appointment of his replacement......Gla Holders, exciting times ahead imho...;-)

On the golf course and so no comment.:-)

Very soon....imho....and long overdue....a strategic JV would be nice....Gla ;-)

Perfectly poised.....Gl;-)

Tree shake over, and bouncing nicely and still cheap as chips.....potential Transformational news getting closer and closer...Gla Holders..:-)

Lol Nolupus, get it right mate......Evgen hasn't got a Chief, news of his appointment coming soon which could be connected to a strategic JV investment with any luck, and it won't just be the noise level but more likely the sp level multiplied by 10 ...Gla Holders....On and UP!!! ;-)

The following reasearch paper was released November 2019 by the highly prestigous University of Rochester in New York, and 3 months later they signed a MoU with Evgen to undertake a clinical trial on SFX-01 in patients with CKD.....Development news could drop at anytime, on another potential transformational blockbuster. Gla ;-)

........................

GSTM1 Deletion Exaggerates Kidney Injury in Experimental Mouse Models and Confers the Protective Effect of Cruciferous Vegetables in Mice and Humans

November 2019

Significance Statement

GSTM1 encodes a member of a superfamily of antioxidant enzymes, and a highly prevalent GSTM1 deletion variant is associated with kidney disease progression in two human study cohorts. In this study, the authors demonstrate that Gstm1 knockout mice exhibit increased oxidative stress, kidney injury, and inflammation in models of CKD and hypertension, and that Gstm1 loss in the parenchyma but not in bone marrow–derived cells drives renal inflammation. Importantly, consumption of broccoli powder or cruciferous vegetables was protective against kidney disease only in Gstm1 knockout mice, and was observed mainly in the human participants in the Atherosclerosis Risk in Communities Study who were homozygous for GSTM1 deletion. These findings suggest that targeting antioxidant therapy specifically in individuals carrying the GSTM1 deletion variant may be effective in delaying kidney disease progression.

hTtps://jasn.asnjournals.org/content/31/1/102.abstract

..................................

Evgen Pharma PLC University of Rochester Collaboration

13/02/2020

Professor Le and colleagues have previously published research showing an association between CKD patients with the GSTM1 null allele and more rapid CKD progression, and also that consumption of cruciferous vegetables (a source of sulforaphane) is associated with lower risks of kidney failure, with stronger effects in those having the GSTM1 null allele. On this basis, Professor Le approached Evgen, the developer of SFX-01, a stable form of sulforaphane that has demonstrated excellent safety and tolerability in previous clinical trials.

Thu Le, Professor of Medicine, and Chief of the Division of Nephrology at the University of Rochester Medical Center said: "We are pleased that Evgen will support our plans to undertake a clinical trial on SFX-01 in patients with CKD. Increased oxidative stress is a major molecular underpinning of CKD progression and our research suggests that patients with the GSTM1 null allele may particularly benefit from sulforaphane treatment via SFX-01 dosing."

hTtps://uk.advfn.com/stock-market/london/evgen-pharma-EVG/share-news/Evgen-Pharma-PLC-

Ps and another one at 425k and 250k ....;-)

0  0 0

A very nice 500k buy at 12p....all bodes well. :-)

A nice 150k buy at 12p.....good news stacking UP imho....news of the new CEO must be close, maybe even a JV and or a strategic investment partner ..... Gla ;-)

Maybe just a coincidence , but there have been no reported Coivid-19 deaths in Scotland since 12th July.....Gla ;-)

...............................

Scottish numbers: 20 July 2020

7 new confirmed cases of COVID-19
0 new reported death(s) of people who have tested positive

A total of 323,452 people in Scotland have been tested through NHS Scotland labs and UK Government Labs to date. Of these:

305,000 were confirmed negative
18,452 were positive

This will be an underestimate of the number of cases. Not everyone with the virus will display symptoms and not all those with symptoms will be tested.

Of the people who have tested positive:

4,146 inpatients have been discharged from hospital since 5 March (this is a decrease of one from the previous cumulative total, resulting from ongoing reviews and further analysis of cases by PHS and Health Boards)
299 were in hospital last night: 3 of whom were in intensive care; plus 7 more person in intensive care with suspected COVID-19
2,491 have died
.............................................

16/6/20

"with patients offered the chance to participate immediately after their diagnosis"

Researchers secured funding from LifeArc to conduct an investigator led, prospective, randomised, double-blind placebo-controlled trial, conducted in the UK, of patients hospitalised with COVID-19.

Investigating a sample size of 300 subjects, the study will compare outcomes for 300mg SFX-01 taken orally, once daily, plus best standard of care (BSC) versus placebo taken orally, once daily plus BSC. The primary outcome of the trial is the clinical status of patients on day 15 based on a seven point scale, recommended by the World Health Organisation as the optimal clinical trial endpoint for COVID-19 studies.

The trial will be conducted in up to six sites across Scotland and the north of England with first patient visit anticipated to happen in July.

https://www.lifearc.org/funding/covid-19-funding/sfx-01/

0  0 0

On the Top 10 riser board on no news....spotlight and investor focus long overdue. Gla holders, BIG news heading this way imho..;-)

Potential Investigator-Led Clinical Collaborations

"We are working with patient groups to plan a grant application for a Phase II clinical trial programme on SFX-01 in children with ASD, hoping to recruit from a consortium of UK hospitals.

Our interest, and that of the parents of some children with ASD, was first triggered when a small clinical study showed that sulforaphane helped improve quality of life in autistic young people.

Our end goal is improving the range of treatment options available for autistic young people, in order to improve quality of life and independence.

” Dr Michael Absoud, a consultantin paediatric neurodisability"We are delighted that Evgenwill support our plans to undertake a clinical trial on SFX-01 in patients with NASH. Oxidative stress is pivotal to the development of NASH and our research suggests that activation of the Nrf2 pathway, which in turn reduces oxidative stress, can reverse the pathology.

”John Dillon,Professor of Hepatology and Gastrenterology, University of Dundee's the School of Medicine "We are pleased that Evgen will support our plans to undertake a clinical trial on SFX-01 in patients with CKD.

Increased oxidative stress is a major molecular underpinning of CKD progression and our research suggests that patients with the GSTM1 null allele may particularly benefit from sulforaphane treatment via SFX-01 dosing.’’ Thu Le, Professor of Medicine and Chief of the Division of Nephrology at the University of Rochester Medical Center, New York.

Next steps and summary

Focus on the strong efficacy data in breast cancer by planning and executing a Phase IIb trial

PhaseII/III trial in ARDS patients commencing shortly

Reduce risk and increase probability ofsuccess by expanding breadth of clinical programmes:

Grant-funded, investigator-led clinical trials (no/smallcost to Evgen)

Inindications with a strong mechanistic rationale (four collaborations announced todate in non-cancer indications)

Seek commercial partnerships based on PhaseII results

Continue to explore other opportunities to monetise our IP assets

CEO recruitment process well-advanced

Investor Presentation June 2020

http://evgen.com/wp-content/uploads/2020/07/EVG-Investor-Presentation-06Jul20-FINAL.pdf

............................
AGM Presentation 16th July 2020

http://evgen.com/wp-content/uploads/2020/07/2020-AGM-presentation-16July20.pdf

Back to 12p plus plus soon enough, in anticipation of imminent news.... we're waiting news of the appointment of the new CEO, which must be imminent imho, which could add significant value to proceedings, dependent on his background, and whether or not if he's connected to any potential JV, and or strategic commercial partnership investment, which would certainly explain the massive volume transfer of shares that have been witnessed over the last couple of months. SFX-01 for Breast Cancer is in planned progress for phase 2/3 trials and so an early JV could be more than likely given the outstanding phase 2 results that were "life changing for some patients "....Gla holders, undoubted significant upside potential and prospects. :-)